Clopidogrel (Plavix) DNA Test - CYP2C19

Several recent landmark studies have proven the importance of 2C19 genotyping in treatment using clopidogrel or Plavix. Researchers have found that patients with variations in a gene called cytochrome P-450 2C19 (CYP2C19) have a 3.58 times greater risk for major adverse cardiovascular events such as death, heart attack, and stroke; the risk was greatest in CYP2C19 poor metabolizers. The abstract is available in the online verison of the New England Journal of Medicine.

Population Frequency of Cytochrome P450 (CYP) 2C19 Metabolizer Types

*There is wide variability among populations. People of Asian and African
ancestry have a a greatly increased prevalence of poor metabolizer status.

CYP2C19 is not just involved in the metabolism of clopidogrel, it metabolizes many other medications including antidepressants, barbituates, proton pump inhibitors, antimalarial and antitumor drugs.

Who Should Be Tested
The CYP2C19 test for clopidogrel or Plavix is considered appropriate for any patient taking or considering this medication.

The Testing Process

The process is simple. You can order testing directly if you have a physician prescription or your healthcare provider can request testing for you. We send a cheek swab collection kit with directions by mail. Use the return mailer to submit samples and receive results in ten days or less. Faster testing is available for an additional charge. Call a DNA testing consultant at (800) 523-3080 for details and to order.

Included with each Genelex CYP2C19 test is 90-days access to GeneMedRx drug and gene interaction software so healthcare providers can see the effect of the genotype on all of your medications, herbals, and over-the counter medicines.